No Data
Express News | This week, 10 listed companies announced the details related to share repurchase and additional loan disclosures. Hangzhou Hikvision Digital Technology plans to use its own funds and special loans of 2 billion to -2.5 billion yuan to repurchase shares.
Jiangzhong Pharmaceutical (600750.SH): The controlling Shareholder has obtained a commitment letter for a special loan for Shareholding in Stocks.
On December 10, Gelonghui reported that Jiangzhong Pharmaceutical (600750.SH) announced that on December 9, 2024, it received a notice from its controlling shareholder China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "China Resources Jiangzhong"). China Resources Jiangzhong has recently obtained a loan commitment letter issued by the Nanchang Donghu Branch of the Industrial And Commercial Bank Of China (hereinafter referred to as "ICBC Nanchang Donghu Branch"). ICBC Nanchang Donghu Branch intends to provide a loan limit of no more than 0.084 billion yuan to China Resources Jiangzhong for its shareholding increase plan, with a loan term of 12 months.
Express News | Jiangzhong Pharmaceutical: The controlling shareholder China Resources Jiangzhong has obtained a loan limit of up to 0.084 billion yuan for Shareholding in the company's shares.
Express News | Under the guidance of market cap management policies, state-owned enterprises are intensively buying back and increasing their shareholding.
Jiangzhong Pharmaceutical (600750): The leading OTC gastrointestinal category leader in China.
Initiate coverage of Jiangzhong Pharmaceutical for the first time with a "buy" rating and a target price of 28.91 yuan. The company is a business unit under China Resources Group that focuses on chinese patent medicine and health products. In recent years, through organic growth and external expansion, OTC revenue growth has outperformed the industry.
China Resources Pharmaceutical Group's Unit Posts Higher Profit in January-September
No Data